March 25 (Reuters) - Regeneron Pharmaceuticals said on Monday the U.S. Food and Drug Administration has declined to approve its blood cancer therapy for two most common subtypes of non-Hodgkin lymphoma due to an issue related to the enrollment status of the confirmatory trials. (Reporting by Sneha S K, Puyaan Singh and Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
883.2 USD | -0.84% | -1.52% | +0.56% |
Apr. 26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
Apr. 26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.56% | 95.28B | |
-2.31% | 103B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B | |
-24.71% | 8.24B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- US FDA declines to approve Regeneron's blood cancer therapy